Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MER3101 in Type 1 Diabetes
NCT03624062Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Aug 2020
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MER3101 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by University of Colorado Denver. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 43 months and Immunologic Analysis at 43 months. Started Aug 2020; status: completed.
02
Drugs
MER3101
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03624062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624062.